Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 Feb 10;312(7027):357–364. doi: 10.1136/bmj.312.7027.357

A rational approach to the management of hepatitis C infection.

G M Dusheiko 1, S Khakoo 1, P Soni 1, L Grellier 1
PMCID: PMC2350276  PMID: 8611836

Full text

PDF
358

Images in this article

358p358-a
on p.358

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attili A. F., Rusticali A., Varriale M., Carli L., Repice A. M., Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol. 1994 Mar;20(3):315–320. doi: 10.1016/s0168-8278(94)80001-4. [DOI] [PubMed] [Google Scholar]
  2. Beloqui O., Prieto J., Suárez M., Gil B., Qian C. H., García N., Civeira M. P. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993 Aug;13(4):279–282. doi: 10.1089/jir.1993.13.279. [DOI] [PubMed] [Google Scholar]
  3. Brillanti S., Garson J., Foli M., Whitby K., Deaville R., Masci C., Miglioli M., Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994 Sep;107(3):812–817. doi: 10.1016/0016-5085(94)90131-7. [DOI] [PubMed] [Google Scholar]
  4. Chemello L., Bonetti P., Cavalletto L., Talato F., Donadon V., Casarin P., Belussi F., Frezza M., Noventa F., Pontisso P. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 1995 Sep;22(3):700–706. doi: 10.1002/hep.1840220303. [DOI] [PubMed] [Google Scholar]
  5. Clemente M. G., Congia M., Lai M. E., Lilliu F., Lampis R., Frau F., Frau M. R., Faa G., Diana G., Dessì C. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr. 1994 Jul;125(1):123–128. doi: 10.1016/s0022-3476(94)70138-5. [DOI] [PubMed] [Google Scholar]
  6. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  7. Di Bisceglie A. M., Axiotis C. A., Hoofnagle J. H., Bacon B. R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992 Jun;102(6):2108–2113. doi: 10.1016/0016-5085(92)90339-z. [DOI] [PubMed] [Google Scholar]
  8. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  9. Dusheiko G. M., Smith M., Scheuer P. J. Hepatitis C virus transmitted by human bite. Lancet. 1990 Aug 25;336(8713):503–504. doi: 10.1016/0140-6736(90)92049-n. [DOI] [PubMed] [Google Scholar]
  10. Dusheiko G., Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. J Viral Hepat. 1994;1(1):3–15. doi: 10.1111/j.1365-2893.1994.tb00057.x. [DOI] [PubMed] [Google Scholar]
  11. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996 Jan 11;334(2):77–81. doi: 10.1056/NEJM199601113340203. [DOI] [PubMed] [Google Scholar]
  12. Eyster M. E., Alter H. J., Aledort L. M., Quan S., Hatzakis A., Goedert J. J. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991 Nov 15;115(10):764–768. doi: 10.7326/0003-4819-115-10-764. [DOI] [PubMed] [Google Scholar]
  13. Fernandez H., Banks G., Smith R. Ribavirin: a clinical overview. Eur J Epidemiol. 1986 Mar;2(1):1–14. doi: 10.1007/BF00152711. [DOI] [PubMed] [Google Scholar]
  14. Ferrari C., Valli A., Galati L., Penna A., Scaccaglia P., Giuberti T., Schianchi C., Missale G., Marin M. G., Fiaccadori F. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology. 1994 Feb;19(2):286–295. [PubMed] [Google Scholar]
  15. García-Buey L., García-Monzón C., Rodriguez S., Borque M. J., García-Sánchez A., Iglesias R., DeCastro M., Mateos F. G., Vicario J. L., Balas A. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995 Jun;108(6):1770–1777. doi: 10.1016/0016-5085(95)90139-6. [DOI] [PubMed] [Google Scholar]
  16. Girelli C. M., Mirata C., Lesinigo E., Casiraghi A. Iron overload and response to alpha-interferon in chronic hepatitis C. Am J Gastroenterol. 1995 Jan;90(1):170–171. [PubMed] [Google Scholar]
  17. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994 Jul;89(7):986–988. [PubMed] [Google Scholar]
  18. Kanai K., Kako M., Aikawa T., Kumada T., Kawasaki T., Hatahara T., Oka Y., Mizokami M., Sakai T., Iwata K. HCV RNA monitoring for tailored regimens of interferon therapy in hepatitis C. Biomed Pharmacother. 1995;49(2):65–67. doi: 10.1016/0753-3322(96)82588-1. [DOI] [PubMed] [Google Scholar]
  19. Lenzi M., Johnson P. J., McFarlane I. G., Ballardini G., Smith H. M., McFarlane B. M., Bridger C., Vergani D., Bianchi F. B., Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991 Aug 3;338(8762):277–280. doi: 10.1016/0140-6736(91)90418-o. [DOI] [PubMed] [Google Scholar]
  20. Lesniewski R., Okasinski G., Carrick R., Van Sant C., Desai S., Johnson R., Scheffel J., Moore B., Mushahwar I. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol. 1995 Apr;45(4):415–422. doi: 10.1002/jmv.1890450411. [DOI] [PubMed] [Google Scholar]
  21. Lok A. S., Lai C. L., Leung E. K. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology. 1990 Dec;12(6):1266–1270. doi: 10.1002/hep.1840120603. [DOI] [PubMed] [Google Scholar]
  22. Mayet W. J., Hess G., Gerken G., Rossol S., Voth R., Manns M., Meyer zum Büschenfelde K. H. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 1989 Jul;10(1):24–28. doi: 10.1002/hep.1840100106. [DOI] [PubMed] [Google Scholar]
  23. Miyakawa H., Sato C., Izumi N., Tazawa J., Ebata A., Hattori K., Sakai H., Ikeda T., Hirata R., Sakai Y. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol Suppl. 1993;1A:85–90. doi: 10.1093/alcalc/28.supplement_1a.85. [DOI] [PubMed] [Google Scholar]
  24. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., Shiomi S., Seki S., Kobayashi K., Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995 Oct 21;346(8982):1051–1055. doi: 10.1016/s0140-6736(95)91739-x. [DOI] [PubMed] [Google Scholar]
  25. Orito E., Mizokami M., Suzuki K., Ohba K., Ohno T., Mori M., Hayashi K., Kato K., Iino S., Lau J. Y. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 1995 Jun;46(2):109–115. doi: 10.1002/jmv.1890460205. [DOI] [PubMed] [Google Scholar]
  26. Poynard T., Bedossa P., Chevallier M., Mathurin P., Lemonnier C., Trepo C., Couzigou P., Payen J. L., Sajus M., Costa J. M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995 Jun 1;332(22):1457–1462. doi: 10.1056/NEJM199506013322201. [DOI] [PubMed] [Google Scholar]
  27. Reichard O., Foberg U., Frydén A., Mattsson L., Norkrans G., Sönnerborg A., Wejstål R., Yun Z. B., Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology. 1994 Feb;19(2):280–285. [PubMed] [Google Scholar]
  28. Renault P. F., Hoofnagle J. H. Side effects of alpha interferon. Semin Liver Dis. 1989 Nov;9(4):273–277. doi: 10.1055/s-2008-1040523. [DOI] [PubMed] [Google Scholar]
  29. Sawada M., Takada A., Takase S., Takada N. Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol Suppl. 1993;1B:85–90. doi: 10.1093/alcalc/28.supplement_1b.85. [DOI] [PubMed] [Google Scholar]
  30. Shindo M., Arai K., Sokawa Y., Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med. 1995 Apr 15;122(8):586–591. doi: 10.7326/0003-4819-122-8-199504150-00005. [DOI] [PubMed] [Google Scholar]
  31. Simmonds P., Alberti A., Alter H. J., Bonino F., Bradley D. W., Brechot C., Brouwer J. T., Chan S. W., Chayama K., Chen D. S. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994 May;19(5):1321–1324. [PubMed] [Google Scholar]
  32. Suzuki T., Tanaka E., Matsumoto A., Urushihara A., Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy. J Med Virol. 1995 Jun;46(2):162–168. doi: 10.1002/jmv.1890460215. [DOI] [PubMed] [Google Scholar]
  33. Takano S., Ito Y., Yokosuka O., Ohto M., Uchiumi K., Hirota K., Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology. 1994 Sep;20(3):558–564. [PubMed] [Google Scholar]
  34. Thaler M. M., Park C. K., Landers D. V., Wara D. W., Houghton M., Veereman-Wauters G., Sweet R. L., Han J. H. Vertical transmission of hepatitis C virus. Lancet. 1991 Jul 6;338(8758):17–18. doi: 10.1016/0140-6736(91)90006-b. [DOI] [PubMed] [Google Scholar]
  35. Van Thiel D. H., Friedlander L., Fagiuoli S., Wright H. I., Irish W., Gavaler J. S. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994 Mar;20(3):410–415. doi: 10.1016/s0168-8278(94)80017-0. [DOI] [PubMed] [Google Scholar]
  36. Yamada G., Takahashi M., Tsuji T., Yoshizawa H., Okamoto H. Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C. Dig Dis Sci. 1992 Dec;37(12):1926–1927. doi: 10.1007/BF01308091. [DOI] [PubMed] [Google Scholar]
  37. Zanetti A. R., Tanzi E., Paccagnini S., Principi N., Pizzocolo G., Caccamo M. L., D'Amico E., Cambiè G., Vecchi L. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet. 1995 Feb 4;345(8945):289–291. doi: 10.1016/s0140-6736(95)90277-5. [DOI] [PubMed] [Google Scholar]
  38. el Gohary A., Hassan A., Nooman Z., Lavanchy D., Mayerat C., el Ayat A., Fawaz N., Gobran F., Ahmed M., Kawano F. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop. 1995 May;59(2):155–161. doi: 10.1016/0001-706x(95)00075-p. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES